Exploring the Impact of Anti-PD-1 and Anti-PD-L1 Agents in Merkel Cell Carcinoma

Findings from a phase 1b study showed that the combination of IO-202 and azacitidine elicited clinical benefits in patients with hypomethylating agent–naive chronic myelomonocytic leukemia.

At the 2024 ASH Annual Meeting, findings suggested that the IPSS-del(5q) Scoring System may more effectively identify risks in MDS with isolated 5q deletions compared to standard MDS scoring systems.

Socioeconomic factors significantly impact access to allogeneic hematopoietic stem cell transplant in patients with acute myeloid leukemia, with certain groups less likely to receive this potentially lifesaving treatment.

Updated phase 2 trial data presented at the 2024 ASH Annual Meeting show that the novel bicistronic CD19/CD22-directed CAR T-cell therapy is safe, durable, and highly effective in children with relapsed/refractory B-ALL.

In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.

The 48-week end points of the MANIFEST-2 study show improvements in spleen reduction, symptoms, bone marrow fibrosis, and other areas by adding pelabresib to a JAK inhibitor in myelofibrosis.